Biomarkers are a big deal in the clinical world: if as a doctor you’re able to take one simple measurement that allows you to look into a patient’s fu...
James Peyer: Why primary indications matter
“Aging” isn’t a disease as recognized by the FDA–not yet anyway. But then how will the companies trialing anti-aging drugs eve...
Diagnosis: Cursed?
The year is 1996, and you’re a doctor with a strange case on your hands. Actually, it’s not just one case–it’s an entire family with a collectio...
Michael Fossel on telomerase therapy in cancer, Alzheimer’s, and more
Last week we heard the theoretical side of Dr. Michael Fossel’s mission to bring aging to its knees, and why his chosen point of attack was on t...
Più mosso, Maestro! An interview in the key of telomere with Dr. Michael Fossel
With three decades of experience as a professor of clinical medicine under his belt, Dr. Michael Fossel takes a fundamentally pragmatic approach to ta...
Longevity orthologs: How far from the apple to the tree?
Laboratories studying the biology of aging are a menagerie of creatures great and small. From unicellular yeast and nematodes, all the way up to prima...
Research roundup: Scientists stop premature aging in its tracks, and more
Researchers from Houston Methodist Research Institute took cells from patients with progeria, a devastating condition that causes premature aging, and...
Flip this epigenome: Making old mice good as new
Scientists at the Salk Institute for Biological Studies knew it could be done in principle–all you had to do to erase the telltale signs of agin...